NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
IGC Pharma, Inc. IGC
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$1.3M
▼ 5.5% vs FY2023
EPS · FY24
$-0.09
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-104.3%
Net margin · FY24
-560.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.3M
Revenue, FY2024 · full 15-year series below
Revenue
Net income
The company lost 560 cents on every revenue dollar this year.
Per share
USD -0.09
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-104.3%
Return on equity, FY2024
ROE
Operating margin-585.8%
Net margin-560.3%
Return on assets-76.4%
Each USD of equity lost 104 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−20.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+47.4%
−20.8%
−16.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2024
Change, 5 years+105.7%
Change, 10 years—
The share count grew 106% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.7M
total assets, end of FY2024
Total assetsUSD 8.7M
EquityUSD 6.3M
CashUSD 405,000.00
Gross debtUSD 137,000.00
Net debtUSD -268,000.00
Current ratio1.28×
The company holds more cash than debt.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.09
−0.22
·
·
−0.21
−0.19
−0.13
−0.06
−0.07
−0.17
−0.31
−0.37
−0.32
−2.66
−1.34
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−104.3
−116.9
−59.3
−53.0
−29.7
−27.6
−50.8
−23.2
−17.9
−20.3
−33.1
−21.5
−15.4
−72.1
−303.6
Shares out B
0.08
0.07
0.05
0.05
0.05
0.04
0.04
0.03
0.03
0.02
0.01
0.01
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed